Revenue and Profit - Revenue for Q1 2022 was CNY 196,784,525.34, a decrease of 21.51% compared to the same period last year[5] - Net profit attributable to shareholders was CNY 11,813,068.13, down 52.13% year-on-year[5] - Basic earnings per share decreased by 52.13% to CNY 0.0844[5] - Total operating revenue for Q1 2022 was ¥196.78 million, a decrease of 21.5% compared to ¥250.72 million in Q1 2021[16] - Net profit for Q1 2022 was ¥6.98 million, a decline of 72.3% from ¥25.16 million in Q1 2021[17] - Basic and diluted earnings per share for Q1 2022 were ¥0.0844, down from ¥0.1763 in Q1 2021[17] Research and Development - R&D investment totaled CNY 12,163,330.21, a decline of 57.55% compared to the previous year[6] - R&D expenditure accounted for 6.18% of revenue, down 5.25 percentage points year-on-year[6] - Research and development expenses decreased significantly to ¥12.16 million in Q1 2022, down 57.5% from ¥28.65 million in Q1 2021[16] Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY -61,042,833.78, indicating a significant cash outflow[5] - Cash flow from operating activities showed a net outflow of ¥61.04 million in Q1 2022, an improvement from a net outflow of ¥68.94 million in Q1 2021[20] - Cash and cash equivalents at the end of Q1 2022 were ¥674.86 million, compared to ¥122.04 million at the end of Q1 2021[21] - The company raised ¥105 million in borrowings during Q1 2022, compared to ¥20 million in Q1 2021[21] - The company reported a net cash outflow from investing activities of ¥43.59 million in Q1 2022, an improvement from a net outflow of ¥125.18 million in Q1 2021[20] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,095,741,507.86, a decrease of 1.65% from the end of the previous year[6] - The company's current assets totaled RMB 1,587,420,061.71, down from RMB 1,613,180,696.33, indicating a decrease of about 1.59%[12][13] - The company's cash and cash equivalents were RMB 674,858,261.75, a decrease from RMB 730,667,550.06, representing a decline of approximately 7.67%[12] - Short-term borrowings increased to RMB 439,188,222.20 from RMB 385,437,402.76, marking an increase of about 13.93%[13][14] - The total liabilities decreased to RMB 694,775,879.97 from RMB 736,886,724.25, reflecting a reduction of approximately 5.71%[14] - The company's total non-current assets were RMB 508,321,446.15, down from RMB 517,688,906.47, indicating a decrease of approximately 1.43%[13] - The company's inventory stood at RMB 57,764,296.23, down from RMB 61,425,161.64, indicating a decrease of approximately 5.39%[12][13] - The accounts receivable increased to RMB 626,970,399.98 from RMB 590,812,642.21, reflecting an increase of about 6.10%[12] Shareholder Information - Shareholders' equity attributable to shareholders increased by 0.85% to CNY 1,405,009,892.50[6] - The total number of common shareholders at the end of the reporting period was 7,110[10] - The company's equity attributable to shareholders rose to RMB 1,405,009,892.50 from RMB 1,393,196,824.37, an increase of about 0.84%[14] - The company's retained earnings improved to -RMB 62,690,123.16 from -RMB 74,503,191.29, showing a positive change in retained earnings[14] Market Conditions - The company experienced a decline in sales due to repeated COVID-19 outbreaks in multiple provinces[7]

Financial Performance - In 2021, the company achieved operating revenue of 684.68 million yuan, a decrease of 37.08% compared to the previous year[4]. - The operating profit was -221.33 million yuan, a decline of 259.58% year-on-year[4]. - The total profit amounted to -221.56 million yuan, down 256.95% from the previous year[4]. - The net profit attributable to shareholders was -166.89 million yuan, representing a decrease of 225.50% year-on-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -178.99 million yuan, a reduction of 242.99% compared to the previous year[4]. - The company's operating revenue for 2021 was approximately ¥684.68 million, a decrease of 37.08% compared to ¥1.09 billion in 2020[23]. - The net profit attributable to shareholders for 2021 was a loss of approximately ¥166.89 million, a decline of 225.50% from a profit of ¥132.98 million in 2020[23]. - The basic earnings per share for 2021 was -¥1.1920, down 217.65% from ¥1.0132 in 2020[23]. - The company's total profit for the year was CNY -221.56 million, a decrease of 256.95% compared to the previous year[33]. - The company reported a net cash flow from operating activities of -63,111,275.75 RMB, an improvement from -290,839,050.88 RMB in the previous year[89]. Research and Development - The company has 21 new products under development, with 2 innovative drug candidates identified and 3 projects in clinical research[34]. - The company applied for 25 new invention patents and obtained 6 new authorized invention patents during the reporting period, totaling 30 authorized patents[34]. - Research and development expenses accounted for 15.03% of operating revenue, an increase of 5.10 percentage points from 9.93% in 2020[23]. - The company’s R&D costs increased due to the pandemic, affecting the progress of clinical trials[33]. - The company is focusing on both innovative and generic drugs to enhance its product line and risk resilience[34]. - The company has established a comprehensive R&D model with dedicated research platforms and partnerships with leading third-party research institutions[42]. - The company has made significant progress in R&D, focusing on both innovative and generic drugs, with a commitment to enhancing its position in the influenza treatment market[47]. - The company has developed three high-success-rate, practical, low-cost, and fast drug molecule design and discovery technologies, forming a core platform for lead compound design and discovery[55]. - The company has a core technology for chiral drug synthesis and quality control, focusing on controlling impurities and ensuring chiral purity in the final products[58]. - The company has a total of 74 patent applications, with 34 patents granted as of December 31, 2021[60]. Market and Sales - The decline in performance is consistent with industry trends, influenced by factors such as the ongoing COVID-19 pandemic and national drug procurement policies[4]. - The company is expanding its marketing network to mitigate the impact of COVID-19 on its product sales[36]. - The company has established a nationwide marketing network covering 30 provinces, enhancing service to end customers and supporting new drug commercialization[75]. - The company is focusing on enhancing its product lines in oncology and cardiovascular diseases, with several innovative drug candidates and generic drug applications in progress[40]. - The company aims to expand its market presence by deepening its sales channels in city and county hospitals, targeting new growth points[147]. Risk Management - The company has disclosed potential risks in the "Management Discussion and Analysis" section of the report[5]. - The company is exposed to risks related to R&D failures and the lengthy drug approval process, which may affect future product launches[79]. - The company is exposed to macroeconomic risks due to ongoing changes in national pharmaceutical policies, which could affect market dynamics and pricing strategies[85]. - The company faced significant impacts from the COVID-19 pandemic, leading to reduced demand for its core product, "Liwei" (Palivizumab Sodium Injection)[76]. Corporate Governance - The company has established a governance structure that includes a shareholders' meeting, board of directors, supervisory board, and senior management, ensuring checks and balances among these entities[152]. - The board of directors consists of eight members, including four independent directors, with a three-year term and a cumulative voting system for transparency in the election process[153]. - The supervisory board is composed of four members, including two employee representatives, ensuring compliance with legal requirements and effective oversight of the company's financials[154]. - The company has implemented a comprehensive internal control system to ensure effective management and oversight, preventing any tendencies of "insider control"[155]. - The company adheres to strict information disclosure regulations, ensuring that all shareholders have equal access to information, thereby enhancing transparency[155]. Financial Strategy - The company plans to issue shares and pay cash to acquire assets, which is expected to improve financial conditions and enhance profitability in the long term[139]. - The company has a cash dividend policy that mandates a minimum of 10% of distributable profits to be distributed as cash dividends if there are no major investment plans[190]. - The proposed profit distribution plan for 2021 is not to distribute cash dividends, nor to issue bonus shares or convert capital reserves into share capital[191]. Operational Efficiency - The company has effectively managed its subsidiaries, improving overall operational efficiency and risk resistance[196]. - The company received a standard unqualified opinion on the effectiveness of its internal control over financial reporting for the year 2021[197]. - The company is actively preparing for the election of a new board of directors and supervisory board, with plans to complete the elections and fulfill disclosure obligations promptly[198].

Financial Performance - The company's operating revenue for the third quarter was ¥134,213,325.60, a decrease of 50.03% compared to the same period last year[5] - The net profit attributable to shareholders was ¥7,061,002.04, down 67.24% year-on-year[5] - The basic earnings per share for the quarter was ¥0.0504, reflecting a decline of 67.24% compared to the previous year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥6,524,246.53, a decrease of 62.84% compared to the same period last year[5] - Total operating revenue for the first three quarters of 2021 was CNY 565,410,643.65, a decrease of 33.4% compared to CNY 849,142,132.03 in the same period of 2020[20] - Net profit for the first three quarters of 2021 was CNY 47,827,466.53, a decline of 36.0% from CNY 74,769,473.79 in 2020[21] - Basic earnings per share for the first three quarters of 2021 were CNY 0.3511, compared to CNY 0.5538 in the same period of 2020[22] Research and Development - Research and development expenses totaled ¥17,673,886.49, representing 13.17% of operating revenue, an increase of 0.98 percentage points year-on-year[6] - Research and development projects are progressing steadily, with no significant changes in the current reporting period compared to the previous half-year[11] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,311,572,629.25, an increase of 9.92% from the end of the previous year[6] - Current assets totaled CNY 1,940,985,153.41, up from CNY 1,729,597,539.22, indicating an increase of about 12.14%[15] - Total liabilities as of the end of the reporting period were CNY 679,579,857.78, an increase of 42.1% from CNY 478,069,049.51 in the previous year[20] - Non-current liabilities totaled CNY 87,910,993.02, a slight increase from CNY 85,269,728.61 in the previous year[20] - The company has a total of 7,310 common shareholders as of the reporting period[13] - The largest shareholder, Hunan Xiangtou Holding Group Co., Ltd., holds 28.57% of the shares, totaling 40,000,000 shares[13] Cash Flow - The company reported a cash flow from operating activities of -¥193,890,789.30 for the year-to-date[5] - Net cash flow from operating activities was -$193.89 million, compared to -$176.91 million in the previous period, indicating a decline in operational cash generation[25] - Cash received from sales of goods and services in the first three quarters of 2021 was CNY 423,825,017.52, a decrease of 32.1% from CNY 624,977,283.91 in 2020[24] - Cash paid for operating activities was $643.71 million, down from $842.44 million, suggesting improved cost management[25] - Cash inflow from financing activities amounted to $435 million, compared to $1.35 billion in the previous period, reflecting a decrease in financing receipts[26] - Net cash flow from financing activities was $164.63 million, down from $1.10 billion in the prior period, indicating reduced financing activity[26] Inventory and Receivables - Accounts receivable increased to CNY 855,073,412.28 from CNY 702,977,210.62, representing a growth of around 21.63%[15] - Inventory levels rose to CNY 96,503,106.62 from CNY 48,647,769.15, reflecting an increase of about 98.24%[16] - The company reported a significant increase in accounts payable, which rose to CNY 37,906,234.06 from CNY 20,207,678.52, representing an increase of approximately 87.51%[16] Market Impact - The decline in revenue and profit was primarily attributed to the ongoing impact of the pandemic on market sales and logistics[11]

Financial Performance - The company reported a total revenue of 500 million CNY for the first half of 2021, representing a 20% increase compared to the same period last year[14]. - The net profit for the first half of 2021 was 100 million CNY, which is a 15% increase year-over-year[14]. - The company's operating revenue for the first half of 2021 was ¥431.20 million, a decrease of 25.73% compared to ¥580.56 million in the same period last year[20]. - The net profit attributable to shareholders for the first half of 2021 was ¥42.09 million, down 15.00% from ¥49.52 million year-on-year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 36.37% to ¥31.54 million from ¥49.57 million in the previous year[20]. - The company has set a performance guidance for the full year 2021, projecting a revenue target of 1.2 billion CNY, which would represent a 20% increase from 2020[14]. Research and Development - Research and development expenses increased by 25%, totaling 50 million CNY, reflecting the company's commitment to innovation[14]. - The company has a pipeline that includes 7 Class 1 new drug projects and 6 Class 3-4 generic drug projects currently under research[26]. - The company has established a comprehensive R&D platform, including research institutes and clinical centers, with core technical personnel having over ten years of experience in drug development[30]. - The company has developed a core technology platform for drug discovery, which includes high success rate and cost-effective methods for molecular design and discovery of lead compounds[38]. - The company has implemented a "sales-driven production" model, ensuring that all products are produced in-house and adhere to updated GMP standards[31]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a revenue growth of 15% in that region by the end of 2021[14]. - A strategic acquisition of a local biotech firm is expected to enhance the company's product pipeline and is projected to contribute an additional 200 million CNY in revenue over the next two years[14]. - The company is actively pursuing market expansion with a multi-tiered marketing channel across 30 provinces in China[32]. - The company has launched products in the oncology and cardiovascular disease sectors, including unique products like Benazepril Hydrochlorothiazide Tablets and Metafeni Tablets[28]. Sustainability and Compliance - The company is committed to sustainability initiatives, with plans to reduce carbon emissions by 30% by 2025[14]. - The management emphasized the importance of maintaining compliance with regulatory standards to avoid penalties and ensure smooth operations[115]. - The company has established a comprehensive quality management system to ensure product quality, but any unforeseen quality issues could negatively impact brand image and sales[66]. Risks and Challenges - The company has identified potential risks including regulatory changes and market competition, which could impact future performance[14]. - The company faces risks related to R&D failures, including uncertainties in clinical trial approvals and potential setbacks in drug development timelines[63]. - The core product, Palivizumab, is at risk of being replicated by competitors, which could lead to increased market competition and reduced market share[66]. - The company is exposed to macroeconomic risks due to ongoing changes in national pharmaceutical policies, which could affect market dynamics and operational strategies[69]. Shareholder Commitments and Profit Distribution - The company plans to distribute cash dividends amounting to no less than 10% of the available profit for distribution each year, after legal reserves are deducted[101]. - The cumulative cash distribution over the next three years is expected to be at least 30% of the average annual available profit for distribution since the company went public[101]. - The company has committed to not unfairly transferring benefits to other entities or individuals, ensuring the protection of its interests[119]. - The company guarantees that subsidiaries will distribute at least 30% of their available profits to shareholders in cash each year[103]. Financial Position and Assets - The company's total assets increased by 13.32% to ¥2.38 billion compared to ¥2.10 billion at the end of the previous year[20]. - The company's total liabilities were RMB 755,729,500.74, compared to RMB 478,069,049.51, showing an increase of approximately 58.2%[155]. - The company's equity attributable to shareholders was RMB 1,602,173,801.63, slightly up from RMB 1,600,823,793.28, indicating a marginal increase of about 0.1%[155]. - The company's cash and cash equivalents reached RMB 353,538,311.67, compared to RMB 299,350,975.43 at the end of 2020, reflecting a growth of approximately 18.1%[153]. Future Outlook - The company aims to establish itself as a leading enterprise in the antiviral and infectious disease prevention sector, with a focus on a full range of antiviral products[27]. - The company has outlined a future outlook with a revenue target of 3 billion RMB for the next fiscal year, indicating a growth expectation of 25%[124]. - New product development includes the launch of a groundbreaking drug expected to enter the market by Q4 2021, which is projected to generate 500 million RMB in sales[125].

Financial Performance - Operating revenue decreased by 23.00% to CNY 250,724,188.68 year-on-year[6] - Net profit attributable to shareholders decreased by 6.45% to CNY 24,678,193.46 compared to the same period last year[6] - Basic and diluted earnings per share decreased by 6.42% to CNY 0.1763[6] - Total operating revenue for Q1 2021 was ¥250,724,188.68, a decrease of 23.0% compared to ¥325,616,521.18 in Q1 2020[23] - Net profit for Q1 2021 was ¥25,161,556.74, a decrease of 11.7% from ¥28,512,421.77 in Q1 2020[25] - Total profit for Q1 2021 was ¥25,087,572.02, down 27.3% from ¥34,505,344.74 in Q1 2020[24] - The comprehensive income total for Q1 2021 was ¥25,161,556.74, a decrease from ¥28,512,421.77 in Q1 2020[25] Cash Flow - Net cash flow from operating activities was negative at CNY -68,941,958.20, a decrease of 1,036.69% year-on-year[6] - The net cash flow from operating activities for Q1 2021 was -68,941,958.20 RMB, a significant decrease compared to 7,360,155.36 RMB in Q1 2020[29] - The company reported a credit impairment loss of ¥-18,131,552.31 in Q1 2021, compared to ¥-2,840,994.02 in Q1 2020[24] - The company reported a cash outflow of 780,000,000.00 RMB for investment activities, reflecting ongoing investment strategies[31] - The net increase in cash and cash equivalents for Q1 2021 was -177,306,114.68 RMB, contrasting with an increase of 1,134,615,873.92 RMB in Q1 2020[30] Assets and Liabilities - Total assets increased by 8.68% to CNY 2,285,460,145.19 compared to the end of the previous year[6] - Total liabilities rose to CNY 635,393,283.51 from CNY 478,069,049.51, reflecting a significant increase of approximately 33.01%[17] - Current assets totaled CNY 1,923,963,603.73, up from CNY 1,729,597,539.22, indicating an increase of about 11.24%[16] - The total non-current assets amounted to CNY 361,496,541.46, down from CNY 373,376,815.23, indicating a decrease of about 3.19%[16] - The company’s retained earnings increased to CNY 160,563,274.62 from CNY 135,885,081.16, reflecting a growth of approximately 18.19%[18] Shareholder Information - The total number of shareholders was 7,262 at the end of the reporting period[10] - The largest shareholder, Hunan Xiangtou Holding Group Co., Ltd., held 28.57% of the shares[10] Research and Development - R&D expenditure accounted for 11.43% of operating revenue, an increase of 4.68 percentage points compared to the previous year[6] - R&D expenses increased by 30.33% to ¥28,652,554.48, indicating a heightened focus on research and development[12] - Research and development expenses increased to ¥28,652,554.48 in Q1 2021, up 30.4% from ¥21,984,332.59 in Q1 2020[24] Inventory and Operating Costs - Inventory rose by 40.62% to ¥68,406,472.36, attributed to increased raw material stocking[12] - Operating costs decreased by 50.71% to ¥17,672,505.83, reflecting a decline in sales revenue while the proportion of new drugs increased[12] - Total operating costs for Q1 2021 were ¥216,036,295.34, down 25.2% from ¥288,773,259.12 in Q1 2020[24] Investment Income - Investment income reached ¥5,852,041.65, primarily from financial product returns[12] - Total cash inflow from investment activities was 664,578,069.05 RMB, primarily from cash recovered from investments[31]

Financial Performance - The company's operating revenue for 2020 was approximately CNY 1.088 billion, representing a 7.29% increase compared to CNY 1.014 billion in 2019[22]. - The net profit attributable to shareholders for 2020 was approximately CNY 133 million, a 45.37% increase from CNY 91 million in 2019[22]. - The basic earnings per share for 2020 was CNY 1.0132, up 16.30% from CNY 0.8712 in 2019[21]. - The company's total assets at the end of 2020 reached approximately CNY 2.103 billion, a 156.86% increase from CNY 819 million at the end of 2019[22]. - The net profit after deducting non-recurring gains and losses for 2020 was approximately CNY 125 million, a 41.98% increase from CNY 88 million in 2019[22]. - The company's net assets attributable to shareholders at the end of 2020 were approximately CNY 1.601 billion, a 381.36% increase from CNY 333 million at the end of 2019[22]. - The company's operating costs decreased by 5.13% to 109,569,963.53 CNY, attributed to higher sales of high-margin new drugs[87]. - The gross profit margin for the pharmaceutical manufacturing segment improved by 1.32 percentage points to 89.93%[90]. - The company reported a net cash flow from operating activities of -290,839,050.88 CNY, a decline of 993.27% year-on-year, primarily due to extended customer payment cycles[87]. Research and Development - Research and development expenses accounted for 9.93% of operating revenue in 2020, an increase of 2.85 percentage points from 7.08% in 2019[21]. - The total R&D investment increased by 50.54% year-on-year, reaching ¥108,038,020.55, compared to ¥71,764,879.73 in the previous year[55]. - The company applied for 8 new invention patents during the reporting period, bringing the total number of applied patents to 49, with 28 patents granted[54]. - The company has established a comprehensive new drug research and development platform, covering all stages from target analysis to clinical research[71]. - The company is developing a monoclonal antibody for rabies prevention, which is in Phase III clinical trials in both the U.S. and China[32]. - The company is focusing on expanding its product pipeline with innovative therapies targeting influenza and diabetic complications[59]. - The company has multiple innovative drugs and specialty generic drugs in development for oncology, diabetes, and respiratory diseases, including the innovative drug Metafenib Tablets[43]. - The company is advancing clinical research for innovative drugs targeting liver cancer and diabetic nephropathy, among others[33]. Corporate Governance - The company has received a standard unqualified audit report from Tianzhi International Accounting Firm[5]. - The board of directors and senior management have confirmed the accuracy and completeness of the annual report, assuming legal responsibility for any misrepresentation[5]. - The company has confirmed that all directors attended the board meeting, ensuring governance compliance[6]. - The company has not disclosed any special arrangements for corporate governance[6]. - The company emphasizes that forward-looking statements in the report do not constitute a commitment to investors, highlighting investment risks[6]. - The company has established a governance structure that complies with relevant laws and regulations, ensuring the protection of shareholder and creditor rights[199]. Market Strategy and Expansion - The company plans to acquire Xingmeng Biotech, which has 4 innovative drug projects and 5 biosimilar projects under development[31]. - The company has established a multi-tiered marketing channel across 30 provinces in China to enhance product promotion[37]. - The company is actively planning to acquire Xingmeng Biotech to enhance its product pipeline and R&D capabilities, which includes a platform compliant with cGMP standards for drug discovery, clinical trials, and large-scale production[44]. - The company is focusing on increasing market share and brand recognition through refined academic promotion and expanding coverage in county-level hospitals[150]. - The company plans to continue expanding its product offerings and market presence in response to the growing demand in the pharmaceutical industry[109]. Risks and Challenges - The company has described potential risks in the report, advising investors to review the "Risk Factors" section for details[5]. - Risks include potential R&D failures and challenges in obtaining regulatory approvals for new drugs, which could impact market potential[81]. - The company is facing risks from intensified competition in the antiviral drug market, particularly for its core product, Peramivir Sodium Injection[83]. - Future industry policies and regulations may significantly impact the company's operational model and product pricing strategies[85]. Shareholder Returns and Dividends - The company plans to distribute a cash dividend of 2.91 yuan per 10 shares, totaling 40,740,000 yuan (including tax) based on a total share capital of 140,000,000 shares as of December 31, 2020, resulting in a cash dividend payout ratio of 30.64%[5]. - The company has established a cash dividend policy that mandates a minimum annual cash dividend of 10% of the distributable profit if there are no major investment plans[154]. - The company guarantees that the annual cash distribution to all shareholders will not be less than 30% of the distributable profits of its subsidiaries[164]. - The company committed to enhancing the management of raised funds to ensure their legal and reasonable use, with a focus on protecting the interests of investors, especially small and medium-sized investors[175]. Compliance and Legal Matters - The company has not reported any significant accounting errors or changes in accounting policies that would affect the financial statements[181]. - There were no significant lawsuits or arbitration matters during the reporting period, indicating a stable legal environment for the company[183]. - The company has committed to ensuring that the compensation system for directors and senior management is linked to the execution of return measures[177]. - The company will ensure that any related transactions with Nanjing New Pharmaceutical are conducted fairly and transparently, protecting the interests of minority shareholders[166].

2020 年第三季度报告 公司代码：688189 公司简称：南新制药 湖南南新制药股份有限公司 2020 年第三季度报告 1 / 20 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 9 | 2020 年第三季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人杨文逊、主管会计工作负责人李亮及会计机构负责人（会计主管人员）方正东保 证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | | 上年度末 | | 本报告期末比上年度 | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | ...

证券代码：688189 证券简称：南新制药 公告编号：2020-011 湖南南新制药股份有限公司 关于参加湖南辖区上市公司 2020 年度投资者网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为进一步做好投资者关系管理工作，加强与投资者的互动交流，使广大投资 者能更深入全面地了解公司情况，湖南南新制药股份有限公司（以下简称"公 司"）将参加由中国证券监督管理委员会湖南监管局、湖南省上市公司协会与深 圳市全景网络有限公司联合举办的"湖南辖区上市公司 2020 年度投资者网上集 体接待日"活动，现将有关事项公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的互 联网平台举行，投资者可以登录"全景·路演天下"网站（http://rs.p5w.net） 参与本次网上投资者接待日活动。本次活动时间为 2020 年 9 月 11 日（星期五） 下午 15:00—17:00。届时公司董事会秘书、证券事务代表将通过网络在线交流 形式和投资者进行沟通与交流。欢迎广大投资者积极参与。 特此公告。 ...

Financial Performance - The company reported a total revenue of 500 million CNY for the first half of 2020, representing a year-on-year increase of 15%[13]. - The net profit for the same period was 100 million CNY, with a profit margin of 20%[13]. - The company's operating revenue for the first half of 2020 was approximately RMB 580.56 million, representing a year-on-year increase of 27.77% compared to RMB 454.37 million in the same period last year[20]. - The net profit attributable to shareholders of the listed company reached approximately RMB 49.52 million, a year-on-year increase of 40.97% from RMB 35.13 million[20]. - The company reported a significant increase in employee compensation liabilities, rising to CNY 15,298,427.86 from CNY 3,519,655.11, reflecting potential growth in workforce or salary adjustments[126]. - The company reported a total profit of CNY 61,550,494.31 for the first half of 2020, compared to CNY 45,923,499.52 in the previous year, marking an increase of 34%[134]. - The company reported a net profit of ¥69,238,556.50 for the first half of 2020, compared to a net profit of ¥44,669,061.00 in the same period of 2019, indicating an increase of approximately 55.2%[133]. Research and Development - Research and development expenses increased by 30%, totaling 50 million CNY, focusing on innovative drug development[13]. - The company's R&D investment accounted for 7.96% of its operating revenue, an increase of 1.32 percentage points compared to 6.63% in the previous year[21]. - The company has established a product pipeline with 34 varieties and 53 drug approvals, including 3 innovative drugs and 2 modified new drugs under development[27]. - The company is actively advancing the development of anti-influenza drugs, with projects like the palivizumab inhalation solution in Phase I/II clinical trials and the new generation antiviral NX-2016 in preclinical research[52]. - The company has ongoing projects in the antiviral field, including the inhalation solution of Peramivir, which is currently in Phase I/II clinical trials[41]. - The company is developing Metafenin, a third-generation anti-tumor drug, which is currently in Phase Ib/IIa clinical trials[45]. - The company has a strong R&D team with expertise across various disciplines, enhancing its drug development capabilities[51]. Market Expansion and Strategy - The company plans to launch two new products in Q3 2020, aiming to capture an additional 10% market share in the pharmaceutical sector[13]. - The company is expanding its market presence in Southeast Asia, targeting a revenue contribution of 20% from this region by the end of 2021[13]. - A strategic acquisition of a local biotech firm is expected to enhance the company's product pipeline and is projected to close by Q4 2020[13]. - The company has set a performance guidance for the full year 2020, aiming for a revenue growth of 20% compared to 2019[13]. Financial Position and Assets - The total assets of the company at the end of the reporting period were approximately RMB 1.95 billion, an increase of 138.41% compared to RMB 818.72 million at the end of the previous year[20]. - The company's net assets attributable to shareholders increased by 356.26%, reaching approximately RMB 1.52 billion[20]. - Cash and cash equivalents at the end of the period amounted to ¥1,116,942,003.53, representing 57.22% of total assets, a 450.39% increase from the previous year[70]. - The total assets as of June 30, 2020, were CNY 1,951,939,068.08, compared to CNY 818,717,329.92 at the end of 2019, indicating significant growth[126]. Risks and Challenges - The company has identified potential risks related to regulatory changes and market competition, which could impact future performance[13]. - The company is exposed to risks related to the approval of new drug applications and potential competition from generic products[62]. - Future profitability may be impacted by royalty payments of 0.2% on domestic sales of Palivizumab sodium injection starting from 2028[63]. - The company faces risks from potential loss of core technical personnel and the leakage of core technologies[62]. Shareholder Commitments and Dividends - The company plans to distribute cash dividends amounting to no less than 10% of the distributable profits for the year after legal reserves are deducted, with a cumulative distribution of at least 30% of the average annual distributable profits over the last three years post-IPO[85]. - The controlling shareholder committed to submit a stock buyback plan within 10 trading days if the stock price falls below the audited net asset value per share for 20 consecutive trading days[89]. - The company guarantees that cash distributions to shareholders from subsidiaries will not be less than 30% of the subsidiaries' distributable profits for the year[85]. Compliance and Governance - The company has committed to fulfilling all public commitments made during its IPO process and is open to social supervision[100]. - The company has not reported any significant changes in its accounting policies during the reporting period[158]. - The company follows the accounting policies in accordance with the requirements of the Chinese accounting standards[159]. Environmental and Quality Control - The company has established a strict pharmaceutical production quality management system to handle environmental pollutants generated during production, ensuring compliance with environmental regulations[107]. - The company has not experienced any major environmental pollution incidents during the reporting period and has adhered to national environmental laws and regulations[107]. Share Capital and Ownership - The total share capital increased from 105 million shares to 140 million shares after the issuance of 35 million new shares[111]. - The largest shareholder, Hunan Xiangtou Holding Group Co., Ltd., holds 40 million shares, representing 28.57% of the total shares[115]. - The number of shareholders reached 14,284 by the end of the reporting period[113].

Financial Performance - Operating revenue for the period was CNY 325,616,521.18, reflecting a growth of 39.89% compared to the same period last year[6] - Net profit attributable to shareholders increased by 28.22% to CNY 26,378,655.96 year-over-year[6] - Total operating revenue for Q1 2020 reached ¥325,616,521.18, a 39.8% increase from ¥232,767,051.46 in Q1 2019[28] - Net profit for Q1 2020 was ¥28,512,421.77, representing a 38.7% increase compared to ¥20,573,320.06 in Q1 2019[29] - Total profit for Q1 2020 was ¥34,505,344.74, up 34.2% from ¥25,716,650.08 in Q1 2019[28] - Total comprehensive income for Q1 2020 was CNY 15,096,347.65, compared to CNY 9,551,745.58 in Q1 2019, representing a year-over-year increase of approximately 58.5%[33] Assets and Liabilities - Total assets increased by 143.22% to CNY 1,991,252,498.15 compared to the end of the previous year[6] - Total liabilities amounted to ¥470,191,618.25, up from ¥461,451,171.79, indicating a rise in overall debt levels[23] - Current liabilities rose to ¥349,873,229.51 compared to ¥340,705,187.62, showing an increase in short-term financial obligations[22] - The company's total liabilities and equity reached ¥1,767,260,528.57, up from ¥590,376,152.39, showcasing overall financial growth[26] Shareholder Information - The total number of shareholders reached 19,261 by the end of the reporting period[10] - The top ten shareholders held a combined 85.00% of the company's shares, with the largest shareholder owning 28.57%[10] Cash Flow - The net cash flow from operating activities decreased by 90.35% to CNY 7,360,155.36 compared to the previous year[6] - Cash inflow from operating activities for Q1 2020 was CNY 336,025,280.86, compared to CNY 278,356,781.09 in Q1 2019, reflecting a growth of approximately 20.7%[34] - Cash outflow from operating activities totaled CNY 328,665,125.50 in Q1 2020, compared to CNY 202,118,473.59 in Q1 2019, which is an increase of about 62.5%[34] - Cash flow from financing activities showed a significant increase to CNY 1,143,043,149.56, compared to a negative cash flow of CNY 21,099,449.26 in the same period last year, reflecting successful fundraising efforts[12] Research and Development - Research and development expenses accounted for 6.75% of operating revenue, up from 5.98% in the previous year[6] - Research and development expenses increased by 57.96% to CNY 21,984,332.59 in Q1 2020, compared to CNY 13,917,686.16 in Q1 2019, indicating a focus on innovative drug development[12] - The company signed a technology development contract for the project "Oseltamivir Phosphate Dry Suspension" with a total R&D cost of CNY 30 million[13][15] - The company is advancing several new drug projects, including "Mefenamic Acid" for diabetic nephropathy and "Paxlovid" for influenza, with various stages of clinical trials ongoing[19] Earnings Per Share - Basic and diluted earnings per share were CNY 0.1884, down 3.83% from CNY 0.1959 in the previous year[6] - Basic earnings per share for Q1 2020 were ¥0.1884, slightly down from ¥0.1959 in Q1 2019[29]